๐ข ๐๐จ๐ฆ๐ง ๐๐ก: $ImmunityBio(IBRX.US) ImmunityBio Q2 ANKTIVA Revenue Jumps 92% as Regulatory Pipeline Advances
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค Q2 net product revenue reached ๐ฆ๐ฑ๐ฌ.๐ณ ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป, up ๐ต๐ฎ%.โค Revenue increased ๐ญ๐ฑ% sequentially, marking eight consecutive growth quarters.โค First-half product revenue rose ๐ญ๐ฎ๐ญ% to ๐ฆ๐ต๐ฐ.๐ด ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป.โค Cash and marketable securities totaled ๐ฆ๐ฏ๐ฑ๐ณ.๐ฐ ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป.โค FDA set a ๐๐ฎ๐ป๐๐ฎ๐ฟ๐ ๐ฒ, ๐ฎ๐ฌ๐ฎ๐ณ PDUFA date.โค UAE authorized ๐๐ก๐๐ง๐๐ฉ๐ across broader bladder and lung cancers.โค Q2 adjusted net loss improved to ๐ฆ๐ด๐ญ.๐ฌ ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป.โค Reported Q2 net loss widened to ๐ฆ๐ฎ๐ฏ๐ฌ.๐ฐ ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป.โค ImmunityBio secured exclusive U.S. rights to ๐ง๐ผ๐ธ๐๐ผ-๐ญ๐ณ๐ฎ ๐๐๐.โค Multiple regulatory and clinical milestones are expected within ๐ญ๐ฎ months.๐ ๐ช๐ต๐ ๐ง๐ต๐ถ๐ ๐ ๐ฎ๐๐๐ฒ๐ฟ๐:โค Strong ANKTIVA growth signals expanding physician adoption and commercial traction.โค Broader approvals could significantly expand ImmunityBioโs addressable oncology market.โค The January 2027 FDA decision represents a major near-term catalyst.โค Improved adjusted losses suggest stronger underlying operating performance.โค The large reported loss remains a key financial risk for investors.๐ ๐๐ ๐ฝ๐ฒ๐ฟ๐ ๐ฆ๐๐ฎ๐๐ฒ๐บ๐ฒ๐ป๐๐:๐ฅ๐ถ๐ฐ๐ต๐ฎ๐ฟ๐ฑ ๐๐ฑ๐ฐ๐ผ๐ฐ๐ธ, President and CEO of ImmunityBio:โOur record quarterly net product revenue of $50.7 million and eighth consecutive quarter of sequential growth reflect continued physician adoption of ANKTIVA and disciplined commercial execution,โ said Richard Adcock, President and CEO of ImmunityBio. โAt the same time, we continue to invest in expanding ANKTIVAโs global commercial footprint while advancing a focused late-stage clinical pipeline that we believe will create additional opportunities across multiple oncology indications. With $357.4 million in cash and cash equivalents, and marketable securities, we are well-positioned to support both our commercial and clinical priorities.โ๐ฃ๐ฎ๐๐ฟ๐ถ๐ฐ๐ธ ๐ฆ๐ผ๐ผ๐ป-๐ฆ๐ต๐ถ๐ผ๐ป๐ด, ๐ .๐., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio:โThe continued adoption of ANKTIVA in clinical practice reinforces the potential of our IL-15 receptor agonist platform to activate the bodyโs natural killer and T cells to fight cancer,โ said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. โAs we continue generating clinical evidence across multiple tumor types, including bladder cancer, lung cancer, and hematologic malignancies, we remain focused on expanding the potential applications of this platform to address additional areas of significant unmet medical need.โ
Share your thoughtsWhat's on your mind?
0 / 2,000
- H
๐ข ๐๐จ๐ฆ๐ง ๐๐ก: $ImmunityBio(IBRX.US) ImmunityBio's ANKTIVA Wins Broad UAE Approval for Bladder and Lung Cancer
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค ๐จ๐๐ grants marketing authorization for ๐๐ก๐๐ง๐๐ฉ๐ across two cancer indications.โค Authorization expands ANKTIVA's global regulatory footprint to ๐ฏ๐ฐ ๐ฐ๐ผ๐๐ป๐๐ฟ๐ถ๐ฒ๐.โค UAE becomes the ๐ฑ๐๐ต regulatory jurisdiction to approve ANKTIVA.โค Approval includes the broadest ๐๐๐-๐๐ป๐ฟ๐ฒ๐๐ฝ๐ผ๐ป๐๐ถ๐๐ฒ ๐ก๐ ๐๐๐ label to date.โค First global approval covering ๐๐๐ฆ with or without papillary tumors and papillary-only disease.โค ANKTIVA also approved for metastatic ๐ก๐ฆ๐๐๐ after checkpoint inhibitor failure.โค NMIBC trial achieved ๐ณ๐ญ% complete response rate in CIS patients.โค Papillary-only cohort reported ๐ฑ๐ด.๐ฎ% 12-month disease-free survival.โค NSCLC study reported median overall survival of ๐ญ๐ฐ.๐ฒ ๐บ๐ผ๐ป๐๐ต๐.๐ ๐ช๐ต๐ ๐ง๐ต๐ถ๐ ๐ ๐ฎ๐๐๐ฒ๐ฟ๐:โค Expands commercial opportunity with approvals across ๐ฏ๐ฐ ๐ฐ๐ผ๐๐ป๐๐ฟ๐ถ๐ฒ๐.โค Broad NMIBC label could significantly increase ANKTIVA's eligible patient population.โค Adds a new treatment option for patients with limited post-BCG or post-checkpoint therapies.โค Strengthens ๐๐บ๐บ๐๐ป๐ถ๐๐๐๐ถ๐ผ's global regulatory and commercialization strategy.๐ ๐๐ ๐ฝ๐ฒ๐ฟ๐ ๐ฆ๐๐ฎ๐๐ฒ๐บ๐ฒ๐ป๐:๐ฃ๐ฎ๐๐ฟ๐ถ๐ฐ๐ธ ๐ฆ๐ผ๐ผ๐ป-๐ฆ๐ต๐ถ๐ผ๐ป๐ด, ๐ .๐., Founder, Executive Chairman and Global Chief Medical and Scientific Officer of ImmunityBio:โFor patients with BCG-unresponsive bladder cancer, the choice has too often been between losing the bladder and running out of options. This approval by the Emirates Drug Establishment is the first in the world to reach across the entire spectrum of non-muscle invasive bladder cancer from carcinoma in situ with or without papillary tumors, and, for the first time, papillary disease alone. Since the National Cancer Institute ranked IL-15 as the number one priority cytokine for cancer immunotherapy in 2007, we have worked to translate that biology into an immunotherapy that activates the trifecta of natural killer cells, CD8+ killer T cells, and memory T cells to deliver durable responses. That same immunological backbone now extends to lung cancer, where ANKTIVA, by stimulating NK cells which target tumor cells that have lost MHC-I T cell receptors, can restore the immune response in patients whose disease has progressed on checkpoint therapy. This approval in lung cancer patients who failed checkpoint inhibitors supports the evidence that the MHC-I receptor is lost in patients who progressed on checkpoint inhibitors.โ - H
๐ข ๐๐๐๐ ๐๐: FDA Accepts $ImmunityBio(IBRX.US) ImmunityBioโs ANKTIVA Label Expansion Application
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค FDA accepts ImmunityBioโs ๐ฌ๐ฎ๐ฉ๐ฉ๐ฅ๐๐ฆ๐๐ง๐ญ๐๐ฅ ๐๐๐ for ANKTIVA plus BCG.โค Filing targets ๐๐๐-๐ฎ๐ง๐ซ๐๐ฌ๐ฉ๐จ๐ง๐ฌ๐ข๐ฏ๐ bladder cancer with papillary disease.โค FDA assigns ๐๐๐ง. ๐, ๐๐๐๐ target action date.โค Expansion seeks inclusion of patients without ๐๐๐ซ๐๐ข๐ง๐จ๐ฆ๐ ๐ข๐ง ๐ฌ๐ข๐ญ๐ฎ.โค QUILT 3.032 trial showed ๐๐.๐% 12-month disease-free survival rate.โค Approximately ๐๐% of NMIBC patients present with ๐ฉ๐๐ฉ๐ข๐ฅ๐ฅ๐๐ซ๐ฒ ๐๐ข๐ฌ๐๐๐ฌ๐.โค Safety profile remained consistent with ๐๐๐ ๐๐ฅ๐จ๐ง๐, company says - H
๐ข ๐๐๐๐ ๐๐: $ImmunityBio(IBRX.US) ImmunityBio Reports Favorable Bladder Cancer Data at ๐๐๐ ๐๐๐๐
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ๐๐๐๐๐๐๐ยฎ + BCG showed stronger complete response outcomes versus competitors.โค NAI+BCG patients were ๐ร more likely to achieve complete response versus nadofaragene.โค Median complete response duration reached ๐๐.๐ months versus ๐.๐ months.โค NAI+BCG reduced ๐๐ฒ๐ฌ๐ญ๐๐๐ญ๐จ๐ฆ๐ฒ risk by ๐๐% versus nadofaragene.โค Compared with TAR-200, NAI+BCG showed numerically higher ๐๐-๐ฆ๐จ๐ง๐ญ๐ก CR rates.โค NAI+BCG demonstrated significantly fewer ๐ญ๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ-๐ซ๐๐ฅ๐๐ญ๐๐ adverse events than TAR-200.โค Data presented at ๐๐๐ ๐๐๐๐ for BCG-unresponsive bladder cancer patients. - H
โก ๐๐๐๐๐๐: $ImmunityBio(IBRX.US) ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain BCG
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ImmunityBio signs exclusive U.S. agreement with ๐๐๐ฉ๐๐ง ๐๐๐ ๐๐๐๐จ๐ซ๐๐ญ๐จ๐ซ๐ฒ.โค Deal targets long-standing ๐.๐. ๐๐๐ ๐ฌ๐ก๐จ๐ซ๐ญ๐๐ ๐ in bladder cancer treatment.โค Agreement covers development and commercialization of ๐๐จ๐ค๐ฒ๐จ-๐๐๐ ๐๐๐.โค Phase III SWOG S1602 study showed ๐ง๐จ๐ง-๐ข๐ง๐๐๐ซ๐ข๐จ๐ซ๐ข๐ญ๐ฒ versus TICE BCG.โค Tokyo strain achieved ๐๐% ๐-๐ฒ๐๐๐ซ high-grade recurrence-free survival.โค Product remains ๐ข๐ง๐ฏ๐๐ฌ๐ญ๐ข๐ ๐๐ญ๐ข๐จ๐ง๐๐ฅ and unapproved by the FDA in the U.S.โค ImmunityBio plans FDA engagement and ๐๐๐ submission using S1602 data. - W
Top 10 Stocks in Russell 2000 YTD $IWM
๐ข $Rackspace Tech(RXT.US) +495%๐ข $Maxlinear(MXL.US) +427%๐ข $Applied Optoelectronics(AAOI.US) +423%๐ข $Satellogic(SATL.US) +401%๐ข $Aehr Test(AEHR.US) +370%๐ข $agilon health(AGL.US) +349%๐ข $ImmunityBio(IBRX.US) +294%๐ข $Atomera(ATOM.US) +292%๐ข $ICHOR(ICHR.US) +279%๐ข $Bandwidth(BAND.US) +248% - H
๐จ Pre-market buzz!
$Beyond Meat(BYND.US) $Avis Budget(CAR.US) $Navitas Semiconductor(NVTS.US) $Unitedhealth(UNH.US) $Astera Labs(ALAB.US) $AST SpaceMobile(ASTS.US) $ImmunityBio(IBRX.US) $Marvell Tech(MRVL.US) $GE Aerospace(GE.US) $Unusual Machines(UMAC.US) $Amazon(AMZN.US) $RTX(RTX.US) $Bloom Energy(BE.US) $Danaher(DHR.US) $Intel(INTC.US) $Reddit(RDDT.US) $Apple(AAPL.US) $3M(MMM.US) $AXT(AXTI.US)Source: Hardik Shah
